Herb pair of Huangqi-Danggui exerts anti-tumor immunity to breast cancer by upregulating PIK3R1

Abstract

Background: According to traditional Chinese medicine (TCM), drugs supplementing the vital energy, Qi, can eliminate tumors by restoring host immunity. The objective of this study is to investigate the underlying immune mechanisms of anti-tumor activity associated with Qi-supplementing herbs, specifically the paired use of Huangqi and Danggui.

Methods: Analysis of compatibility regularity was conducted to screen the combination of Qi-supplementing TCMs. Using the MTT assay and a transplanted tumor mice model, the anti-tumor effects of combination TCMs were investigated in vitro and in vivo. High content analysis and flow cytometry were then used to evaluate cellular immunity, followed by network pharmacology and molecular docking to dissect the significant active compounds and potential mechanisms. Finally, the anti-tumor activity and the mechanism of the active ingredients were verified by molecular experiments.

Results: There is an optimal combination of Huangqi and Danggui that, administered as an aqueous extract, can activate immunity to suppress tumor and is more effective than each drug on its own in vitro and in vivo. Based on network pharmacology analysis, PIK3R1 is the core target for the anti-tumor immunity activity of combined Huangqi and Danggui. Molecular docking analysis shows 6 components of the combined Danggui and Huangqi extract (quercetin, jaranol, isorhamnetin, kaempferol, calycosin, and suchilactone) that bind to PIK3R1. Jaranol is the most important component against breast cancer. The suchilactone/jaranol combination and, especially, the suchilactone/kaempferol combination are key for immunity enhancement and the anti-tumor effects of the extract.

Conclusions: The combination of Huangqi and Danggui can activate immunity to suppress breast cancer and is more effective than the individual drugs alone.

Keywords

anti-tumor / Danggui / Huangqi / immunity

References

[1] Arafat HM, Omar J, Shafii N, et al. The association between breast cancer and consumption of dairy products: a systematic review. Ann Med. 2023;55:2198256.

[2] Ye F, Dewanjee S, Li Y, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.

[3] Bullock KK, Shattuck-Brandt R, Scalise C, et al. Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC. Cancer Lett. 2024;586:216681.

[4] Liu Z, Zhao X, Shen H, Liu X, Xu X, Fu R. Cellular immunity in the era of modern multiple myeloma therapy. Int J Cancer. 2023;153:1436-1447.

[5] Chen Y, Li H, Fan Y. Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy. Cancer Treat Rev. 2023;120:102606.

[6] Tajaldini M, Poorkhani A, Amiriani T, et al. Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance. Eur J Pharmacol. 2023;957:175991.

[7] Zhou R, Chen S, Wu Q, et al. CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett. 2023;573:216381.

[8] Yang C, Li D, Ko C-N, Wang K, Wang H. Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy. Front Immunol. 2023;14:1133050.

[9] Yan Z, Lai Z, Lin J. Anticancer properties of traditional Chinese medicine. Comb Chem High Throughput Screen. 2017;20:423-429.

[10] Wen S-Y, Chen Y-Y, Deng C-M, Zhang C-Q. Jiang M-M. Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3β/β-catenin signaling pathway. Phytomedicine. 2019;57:352-363.

[11] Borgeaud M, Sandoval J, Obeid M, et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev. 2023;120:102614.

[12] Zheng H, Wang G, Liu M, Cheng H. Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review. Front Oncol. 2023;13:1168226.

[13] Le-Xin C, Ming-Jun L, Chun-Qi X, et al. Yi Qi chu Tan formula (YQCTF) inhibited the progress of lung cancer via regulating tumor-associated neutrophil: An integrated study of network pharmacology, proteomics and pharmacodynamics. J Ethnopharmacol. 2024;318:116943.

[14] Zhao W, Liu Z, Zhang Z, et al. Si Jun zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-κB pathway. J Ethnopharmacol. 2024;318:116948.

[15] Li X, Qu L, Dong Y, et al. A review of recent research progress on the astragalus genus. Molecules. 2014;19:18850-18880.

[16] Gong AGW, Duan R, Wang HY, et al. Evaluation of the pharmaceutical properties and value of astragali radix. Medicines (Basel). 2018;5:46.

[17] Dan L, Hao Y, Song H, et al. Efficacy and potential mechanisms of the main active ingredients of astragalus mongholicus in animal models of liver fibrosis: a systematic review and meta-analysis. J Ethnopharmacol. 2023;319:117198.

[18] Tang L, Wang X, Zhao R, et al. Yi-Qi-Jian-pi formula ameliorates immune function in acute-on-chronic liver failure by upregulating autophagy and mitochondrial biogenesis in CD8+ T lymphocytes. J Ethnopharmacol. 2023;308:116276.

[19] Zheng YM, Shen JZ, Wang Y, Lu AX, Ho WS. Anti-oxidant and anti-cancer activities of Angelica dahurica extract via induction of apoptosis in colon cancer cells. Phytomedicine. 2016;23:1267-1274.

[20] Kang M, Park S, Chung Y, Lim J-O, Kang JS, Park JH. Hematopoietic effects of angelica gigas nakai extract on cyclophosphamide-induced myelosuppression. Plants (Basel). 2022;11:3476.

[21] Lin H-Y, Tsai J-C, Wu L-Y, Peng W-H. Reveals of new candidate active components in Hemerocallis Radix and its anti-depression action of mechanism based on network pharmacology approach. Int J Mol Sci. 2020;21:1868.

[22] Li F, Duan J, Zhao M, et al. A network pharmacology approach to reveal the protective mechanism of Salvia miltiorrhiza-Dalbergia odorifera coupled-herbs on coronary heart disease. Sci Rep. 2019;9:19343.

[23] Huang S-J, Mu F, Li F, et al. Systematic elucidation of the potential mechanism of Erzhi pill against drug-induced liver injury via network pharmacology approach. Evid Based Complement Alternat Med. 2020;2020:6219432.

[24] Guo M-F, Dai Y-J, Gao J-R, Chen P-J. Uncovering the mechanism of Astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology. J Diabetes Res. 2020;2020:5947304.

[25] Lyu M, Zhou Z, Wang X, et al. Network pharmacology-guided development of a novel integrative regimen to prevent acute graft-vs.-host disease. Front Pharmacol. 2018;9:1440.

[26] Wen SY, Liu YT, Wei BY, Ma JQ, Chen YY. PDCD6 promotes hepatocellular carcinoma cell proliferation and metastasis through the AKT/GSK3β/β-catenin pathway. Biomed Environ Sci. 2023;36:241-252.

[27] Chen YY, Ren CF, Wen SY. Polyphyllin D induces G2/M cell cycle arrest via dysfunction of cholesterol biosynthesis in liver cancer cells. Biomed Environ Sci. 2023;36:94-98.

[28] An G, Zheng H, Guo L, et al. A metal-organic framework (MOF) built on surface-modified Cu nanoparticles eliminates tumors via multiple cascading synergistic therapeutic effects. J Colloid Interface Sci. 2024;662:298-312.

[29] So TH, Chan SK, Lee VHF, Chen BZ, Kong FM, Lao LX. Chinese medicine in cancer treatment-how is it Practised in the east and the west? Clin Oncol (R Coll Radiol). 2019;31:578-588.

[30] Chen Y, Bi L, Luo H, et al. Water extract of ginseng and astragalus regulates macrophage polarization and synergistically enhances DDP’s anticancer effect. J Ethnopharmacol. 2019;232:11-20.

[31] Huuhtanen J, Bhattacharya D, Lönnberg T, et al. Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nat Commun. 1981;2022:13.

[32] Ciner AT, Hochster HS, August DA, Carpizo DR, Spencer KR. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review. Immunotherapy. 2021;13:1071-1078.

[33] Lin Y, Yang Z, Xu A, et al. PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway. Sci Rep. 2015;5:8997.

[34] Ai X, Xiang L, Huang Z, et al. Overexpression of PIK3R1 promotes hepatocellular carcinoma progression. Biol Res. 2018;51:52.

[35] Li X, Mak VCY, Zhou Y, et al. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nat Commun. 2019;10:716.

[36] Zeng Q, Lei F, Chang Y, et al. An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer. Biomed Pharmacother. 2019;117:109076.

[37] Nguyen T, Lau A, Bier J, et al. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδsyndrome 2. J Exp Med. 2023;220:e20221020.

[38] Hu L, Zhou Y, Yang J, et al. MicroRNA-7 overexpression positively regulates the CD8+SP cell development via targeting PIK3R1. Exp Cell Res. 2021;407:112824.

[39] Cao L, Ruiz Buendía GA, Fournier N, et al. Resistance mechanism to notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia. Blood Adv. 2023;7:6240-6252.

[40] Wilsher NE, Arroo RR, Matsoukas M-T. Tsatsakis AM, Spandidos DA, Androutsopoulos VP. Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: selective bioactivation of luteolin in breast cancer cells. Food Chem Toxicol. 2017;110:383-394.

[41] Jeong H, Phan ANH, Choi J-W. Anti-cancer effects of polyphenolic compounds in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer. Pharmacogn Mag. 2017;13:595-599.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences